Siga Technologies Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Siga Technologies Inc's ROI in the second quarter of 2026?
Siga Technologies Inc achieved a return on average invested assets (ROI) of 6.45 % in its second quarter of 2026, which is below Siga Technologies Inc's average return on investment, which stands at 28.3%.

ROI fell compared to the first quarter of 2026, despite the net income growth of % from the first quarter of 2026.

Within the Healthcare sector 132 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 475 to 823.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-11.09 %	1.62 %	20.43 %	24.63 %	26.52 %
Y / Y Net Income Change TTM	-85.26 %	-58.31 %	-52.43 %	2244.34 %	4384.25 %
Investment (TTM) in Millions	168	154	212	217	223
Return On Investment (TTM)	6.45 %	10.04 %	10.57 %	33.53 %	38.92 %
SIGA's Overall Ranking	# 823	# 475	# 521	# 146	# 105
Seq. Investment Change TTM	-6.82 %	-8.55 %	-0.82 %	5.2 %	6.5 %
Seq. Net Income Change TTM	-40.13 %	-13.08 %	-68.74 %	-9.38 %	69.34 %
Net Income (TTM) in Millions	12	20	23	74	82

SIGA Company Profile >> Back to SIGA Roi Comparisons >> See Annual SIGA Return On Investment

Return On Investment SIGA's Ranking
Within:	No.
Industry	# 50
Sector	# 133
Overall	# 823

Return On Investment Statistics
High	Average	Low
815.79 %	28.3 %	-239.96 %
(Dec 31 2018)		(Sep 30 2016)

News about Siga Technologies Inc Return on Investment ROI

SIGA Technologies' Appoints Larry Miller as General Counsel, Ushering in a New Era of Legal Excellence in Pursuit of Health Security

March 25, 2024

Introducing Larry Miller: SIGA Technologies Latest Addition Bolsters Legal Team in Pursuit of Health Security Excellence
: March 25, 2024
Publication:
In the ever-evolving landscape of health security and infectious diseases, SIGA Technologies, Inc. (NASDAQ: SIGA), a leading commercial-stage pharmaceutical company, solidifies its commitment to excellence with the appointment of Larry Miller as its general counsel. Effective immediately, Miller brings a wealth of legal expertise and diverse industry experience to fortify SIGA s legal team, propelling the company to new heights in its pursuit of safeguarding global health.
SIGA Technologies has long been renowned for its cutting-edge research and development centered around health security measures and innovative solutions to combat infectious diseases. With the appointment of Larry Miller, the company advances its ambitious agenda, positioning itself as a frontrunner in the pharmaceutical industry s battle against emerging health threats.

SIGA Technologies Appoints Dr. Diem Nguyen as New CEO Amidst Financial Challenges

January 22, 2024

SIGA Technologies, Inc. (SIGA), a prominent pharmaceutical company specializing in the health security market, has recently shared news of the appointment of Dr. Diem Nguyen as their new Chief Executive Officer (CEO). With expertise encompassing a Ph.D. and an MBA, Dr. Nguyen s arrival is anticipated to bring fresh perspective and drive growth for SIGA starting January 27, 2024. Concurrently, the current CEO, Dr. Phil Gomez, will step down from his position the day before, marking the beginning of a new era for the company.
Financial Performance Overview:
Despite the forthcoming leadership transition, SIGA Technologies faces a significant challenge with its financial performance. In the twelve months leading up to the third quarter of 2023, SIGA recorded a cumulative net loss of $-5 million, resulting in a negative return on investment (ROI) of -3.37%. This underwhelming performance places SIGA behind 141 other companies in the healthcare sector that displayed stronger returns on investment. Moreover, the company s total ranking in terms of ROI has considerably deteriorated from 244 to 1837 compared to the second quarter of 2023.

Financial Statements
Siga Technologies Inc's II. Quarter Investments	$ 168 Millions	SIGA's Balance sheet
Siga Technologies Inc's II. Quarter Income	$ 27 Millions	Quarterly SIGA's Income Statement
SIGA's Income by Division		See SIGA's Income by Division

SIGA Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	201	219	200	174	184
Y / Y Investment Growth	-8 %	9.37 %	15.4 %	-5.82 %	32.21 %
Net Income in Millions	23	59	68	34	69
Y / Y Net Income Growth	-60.69 %	-13.01 %	100.76 %	-51.18 %	23.27 %
Annual Return On Investment	11.55 %	27.04 %	33.99 %	19.54 %	37.7 %

Annual Roi Comment

In the fiscal year 2025 ROI decreased relative to the previous year to 11.55 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SIGA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SIGA's Competitors
Subscribers only: Roi for Siga Technologies Inc's Suppliers
Subscribers only: Return On Investment for SIGA's Customers

Other Ratios
SIGA's Roa	SIGA's Inventory Turnover Ratio	SIGA's Growth Rates	SIGA's Dividend Statistics
	SIGA's Profitability Ratios	SIGA's Asset Turnover Ratio	SIGA's Dividend Growth
SIGA's Roe	SIGA's Valuation Ratios	SIGA's Financial Strength Ratios	SIGA's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Neurocrine Biosciences Inc	17.51 %
Intuitive Surgical Inc	17.11 %
Theravance Biopharma inc	17.10 %
Standard Biotools Inc	16.38 %
Inspire Medical Systems inc	16.34 %
Aveanna Healthcare Holdings Inc	16.32 %
Harmony Biosciences Holdings inc	15.85 %
Entera Bio Ltd	15.84 %
Nephros Inc	15.31 %
West Pharmaceutical Services Inc	15.29 %
Progyny Inc	15.25 %
Biolife Solutions Inc	14.83 %
Sbc Medical Group Holdings Incorporated	14.78 %
Spero Therapeutics Inc	14.54 %
Insulet Corporation	14.30 %
Alpha Pro Tech Ltd	13.80 %
Bristol myers Squibb Company	13.58 %
Transmedics Group Inc	13.46 %
Strata Critical Medical Inc	13.34 %
Johnson and Johnson	13.30 %
Amgen Inc	13.08 %
Medinotec Inc	13.06 %
Lantheus Holdings Inc	13.02 %
Msa Safety Inc	13.02 %
Universal Health Services Inc	12.43 %
Ufp Technologies Inc	12.12 %
Solventum Corporation	11.98 %
Ligand Pharmaceuticals Incorporated	11.93 %
Lifevantage Corp	11.84 %
Regeneron Pharmaceuticals Inc	11.83 %

Date modified: 2026-09-08T22:13:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.